The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
Antonio Olveira,
Salvador Augustin,
Salvador Benlloch,
Javier Ampuero,
Jorge Alonso Suárez-Pérez,
Susana Armesto,
Eva Vilarrasa,
Isabel Belinchón-Romero,
Pedro Herranz,
Javier Crespo,
Francisco Guimerá,
Lara Gómez-Labrador,
Víctor Martín,
José Manuel Carrascosa
Affiliations
Antonio Olveira
Department of Digestive Diseases, La Paz University Hospital, 28046 Madrid, Spain
Salvador Augustin
Liver Unit, Vall d’Hebron Hospital Universitari, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
Salvador Benlloch
Department of Digestive Diseases, Arnau de Vilanova Hospital, Centro Biomédico en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 46015 Valencia, Spain
Javier Ampuero
Department of Digestive Diseases, Virgen del Rocío University Hospital, Lab 213, Institute of Biomedicine of Sevilla (IBIS), Department of Medicine, University of Sevilla, Centro Biomédico en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 41004 Sevilla, Spain
Jorge Alonso Suárez-Pérez
Department of Dermatology, Virgen de la Victoria University Hospital, 29010 Málaga, Spain
Susana Armesto
Department of Dermatology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Eva Vilarrasa
Department of Dermatology, Santa Creu i Sant Pau Hospital, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
Isabel Belinchón-Romero
Dermatology Department, Alicante University General Hospital, Institute for Health and Biomedical Research (ISABIAL), Miguel Hernández University of Elche, 03202 Alicante, Spain
Pedro Herranz
Department of Dermatology, La Paz University Hospital, 28046 Madrid, Spain
Javier Crespo
Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, IDIVAL, School Medicine, University of Cantabria, 39005 Santander, Spain
Francisco Guimerá
Dermatology and Pathology Department, Canarias University Hospital, 38320 La Laguna, Spain
Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and Tγδ cells) also contribute to the production of IL-17. In hepatocytes, IL-17 mediates systemic inflammation and the recruitment of inflammatory cells to the liver, and it is also implicated in the development of fibrosis and insulin resistance. IL-17 levels have been correlated with progression from MAFLD to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Clinical trials have shown that inhibiting IL-17A in patients with psoriasis could potentially contribute to the improvement of metabolic and liver parameters. A better understanding of the key factors involved in the pathogenesis of these chronic inflammatory processes could potentially lead to more efficient treatment for both psoriasis and MAFLD, and help to develop holistic strategies to improve the management of these patients.
